Huang Shyh-Min, Li Jing, Armstrong Eric A, Harari Paul M
Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, Wisconsin 53792, USA.
Cancer Res. 2002 Aug 1;62(15):4300-6.
ZD1839 ("Iressa") is an orally-active, selective epidermal growth factor receptor-tyrosinekinase inhibitor. We evaluated the antitumor activity of ZD1839 in combination with radiation in human squamous cell carcinomas (SCCs) of the head and neck. ZD1839 produced a dose-dependent inhibition of cellular proliferation in human SCCs grown in culture. Flow cytometry analysis of cell cycle progression confirmed the accumulation of cells in G(1) phase after exposure to ZD1839. Clonogenic analysis demonstrated that treatment of SCCs with ZD1839 reduced cell survival after radiation exposure. Flow cytometric analysis further demonstrated that treatment of SCCs with ZD1839 amplified radiation-induced apoptosis. Tumor xenograft studies confirmed that oral administration of ZD1839, or focal radiation, resulted in partial and transient tumor regression in both SCC-1 and SCC-6 xenografts. In contrast, profound tumor regression and regrowth delay was observed in mice treated with the combination of ZD1839 and radiation. To examine antiangiogenic effects, we studied the impact of ZD1839 on human umbilical vascular endothelial cells (HUVECs). In the presence of reconstituted Matrigel matrix, HUVECs established a capillary-like network structure (tube formation). Treatment with ZD1839 reduced the cell-to-cell interaction of HUVECs, resulting in disruption of tube formation. The effect of ZD1839 was further examined using an in vivo tumor xenograft model of angiogenesis (Matrigel plug) in athymic mice. Systemic treatment with ZD1839 significantly inhibited tumor-induced neovascularization across the Matrigel plug. Taken together, these results suggest that the antitumor activity of ZD1839 in combination with radiation appears to derive from not only proliferative growth inhibition (with associated cell cycle arrest and enhancement of radiation-induced apoptosis) but also from inhibition of tumor angiogenesis.
ZD1839(“易瑞沙”)是一种口服活性的选择性表皮生长因子受体酪氨酸激酶抑制剂。我们评估了ZD1839联合放疗对头颈部人鳞状细胞癌(SCC)的抗肿瘤活性。ZD1839对培养的人SCC细胞增殖产生剂量依赖性抑制。细胞周期进程的流式细胞术分析证实,暴露于ZD1839后细胞在G(1)期积累。克隆形成分析表明,用ZD1839处理SCC可降低放疗后的细胞存活率。流式细胞术分析进一步表明,用ZD1839处理SCC可增强放疗诱导的细胞凋亡。肿瘤异种移植研究证实,口服ZD1839或局部放疗可导致SCC-1和SCC-6异种移植瘤部分且短暂的肿瘤消退。相比之下,在接受ZD1839与放疗联合治疗的小鼠中观察到显著的肿瘤消退和生长延迟。为了研究抗血管生成作用,我们研究了ZD1839对人脐血管内皮细胞(HUVEC)的影响。在重组基质胶存在的情况下,HUVEC形成了毛细血管样网络结构(管腔形成)。用ZD1839处理可减少HUVEC之间的细胞间相互作用,导致管腔形成破坏。使用无胸腺小鼠体内血管生成肿瘤异种移植模型(基质胶栓)进一步研究了ZD1839的作用。用ZD1839进行全身治疗可显著抑制穿过基质胶栓的肿瘤诱导的新生血管形成。综上所述,这些结果表明,ZD1839联合放疗的抗肿瘤活性似乎不仅源于增殖性生长抑制(伴有相关的细胞周期停滞和放疗诱导细胞凋亡的增强),还源于肿瘤血管生成的抑制。